Positron emission tomography (PET) is an important clinical tool, and with its longer half-life, copper-64 has several unique attributes that make it a multi-purpose radionuclide with many potential applications. Additionally, copper as a trace element plays a pivotal role in several human metabolic and pathologic diseases and is involved in malignant cells biochemistry pathways. This offers the opportunity for scientists to explore the theranostic capabilities of copper-64. This current publication, arising from an IAEA Coordinated Research Project, describes the biochemical and radiopharmaceutical aspects of copper-64, and its clinical applications, with specific guidelines and methods for the production of copper-64 chloride, peptide and monoclonal antibody radiopharmaceuticals. It is expected to be of use to all professionals involved in the field by specifying ideal production, formulation and quality control methods.
The International Atomic Energy Agency (IAEA) is the world's center of cooperation in the nuclear field. It was set up as the world's "Atom's for Peace" organization in 1957 within the United Nations family. The Agency works with its Member States and multiple partners worldwide to promote safe, secure and peaceful nuclear technologies.